|
|
|
|
||
Ingrezza ROW Partnership or Buy OutEvery day that passes without a partnership is a day closer to a buy out. NBIX does not have the infrastructure to go it alone in the EU the next most lucrative market for TD. Teva has a significant International sales force ready to go upon approval in late August. They IMO, will be first to market in the EU so a go it alone strategy for EU is out the window. Time cost money. By the way take a look at Abbvie's Neuro pipeline Ingrezza is a perfect fit. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
43108 | Re: Ingrezza ROW Partnership or Buy Out | movin_on_again | 0 | 6/23/2017 3:17:11 PM |